home Search results for 'Non-Small Cell Lung Cancer'
Medical

More Significant Survival Benefit For Non-Small Cell Lung Cancer Patients Under 55 Years Of Age, Also Using Immunotherapy!

Recent findings show that the use of cutting-edge immune checkpoint inhibitor therapy (referred to as immunotherapy in this article) has increased rapidly over the past decade in the population of patients with advanced non-small cell lung cancer (NSCLC), but the survival benefit is more pronounced in younger people than in older people, who have limited survival benefit with this therapy.

Apparatus

World's 2nd KRAS Inhibitor Approved For Non-Small Cell Lung Cancer With 80% Efficacy!

The FDA has granted accelerated approval to Adagrasib for the treatment of patients with KRAS G12C mutations in non-small cell lung cancer. In the trial, the drug resulted in disease control in 80% of patients, of which, 43% had substantial tumour shrinkage.

Medical

K-Drug Approved For Adjuvant Treatment Of Early-Stage Non-Small Cell Lung Cancer, Significantly Extending Cancer-Free Survival Of Patients!

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.